[Federal Register Volume 74, Number 147 (Monday, August 3, 2009)]
[Pages 38440-38442]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-18504]



National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.


SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of Federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Treatment of Cancer Using Metal Coordinating Compounds That Kill Multi-
Drug Resistant Cancer Cells

    Description of Invention: One of the major hindrances to successful 
cancer chemotherapy is the development of multi-drug resistance (MDR) 
in cancer cells. MDR is frequently caused by the increased expression 
or activity of ABC transporter proteins in response to the toxic agents 
used in chemotherapy. Research has generally been directed to 
overcoming MDR by inhibiting the activity of ABC transporters. However, 
compounds that inhibit ABC transporter activity often elicit strong and 
undesirable side-effects, restricting their usefulness as therapeutics.
    In an alternative approach to reducing the debilitating effects of 
MDR during cancer therapy, scientists at the NIH have identified a 
family of compounds

[[Page 38441]]

whose activities are enhanced, rather than decreased, in MDR cancer 
cells. Particular embodiments of these ``MDR-selective compounds'' 
include certain metal coordinating compounds. Recent evidence suggests 
that these MDR-selective compounds can be used to kill cancer cells 
that overexpress ABC transporters or to re-sensitize multi-drug 
resistant cancer cells to chemotherapeutics. Furthermore, the 
effectiveness of these compositions in killing MDR cancer cells 
correlates directly with the level of ABC transporter expression. 
Importantly, MDR-selective compounds are not inhibitors of ABC 
transporters, thereby reducing the likelihood of undesirable side-
effects during treatment. Thus, MDR-selective compounds represent a 
powerful strategy for treating multi-drug resistant cancers as a direct 
chemotherapeutic and as agents that can re-sensitize MDR cancer cells 
for treatment with additional chemotherapeutic agents.


     Treatment of cancers associated with multi-drug 
resistance, either alone or in combination with other therapeutics.
     Re-sensitization of multi-drug resistant cancer cells to 
chemotherapeutic agents.


     MDR-selective compounds capitalize on one of the most 
common drawbacks to cancer therapies (MDR) by using it as an advantage 
for treating cancer.
     The compositions do not inhibit the function of ABC 
transporters, reducing the chance of side-effects during treatment.
     The effects of MDR-selective compounds correlate with the 
level of ABC transporter expression, allowing healthy cells which do 
not express high levels of ABC transporters to better survive 
    Development Status: Preclinical stage of development.
    Patent Status: U.S. Provisional Application No. 61/182,511 (HHS 
Reference No. E-157-2009/0-US-01).
    Inventors: Gergely Szakacs et al. (NCI).

For More Information, See

     C Hegedus et al. Interaction of ABC multidrug transporters 
with anticancer protein kinase inhibitors: substrates and/or 
inhibitors? Curr Cancer Drug Targets. 2009 May;9(3):252-272.
     MD Hall et al. Synthesis, activity, and pharmacophore 
development for isatin-beta-thiosemicarbazones with selective activity 
toward multidrug-resistant cells. J Med Chem. 2009 May 28;52(10):3191-
     U.S. Patent Application Publication 20080214606 A1 (U.S. 
Patent Application 11/629,233).
    Licensing Status: Available for licensing.
    Licensing Contact: David A. Lambertson, Ph.D.; 301-435-4632; 
    Collaborative Research Opportunity: The Institute of Enzymology is 
seeking statements of capability or interest from parties interested in 
collaborative research to further develop, evaluate, or commercialize 
MDR-selective compounds. Please contact John D. Hewes, Ph.D. at 301-
435-3121 or hewesj@mail.nih.gov for more information.

Non Toxic Peptide Treatment for Dyslipidemic and Vascular Disorders

    Description of Invention: Dyslipidemia and vascular disorders such 
as hyperlipidemia, hypercholesterolemia, HDL deficiency, coronary heart 
disease, atherosclerosis, or thrombic stroke, have become major health 
concerns in recent years. Various approaches to treating these diseases 
have led to mixed success with some undesirable side effects. Long term 
administration of some regimens aimed at reducing cholesterol levels in 
cells can lead to persistent hypertriglyceridemia; a condition that is 
characterized by chronically high triglycerides in the blood. Other 
approaches, such as using peptides to stimulate the efflux of lipids 
from cells, are also associated with high toxicity, which has limited 
their use.
    This technology uses peptide and peptide analogues with multiple 
amphipathic alpha helical domains that have the dual ability to promote 
lipid efflux from cells and stimulate lipoprotein lipase activity, 
without inducing toxicity. It consists of motifs that mimick 
apolipoprotein A-I (apoA-I), the most abundant protein constituent of 
high density lipoproteins (HDLs) that is capable of inducing cellular 
lipid efflux, and motif resembling apolipoprotein C-II (apoC-II), a 
known activator of lipoprotein lipase. Peptides constructed with these 
structural domains are capable of stimulating lipid efflux and 
activating lipoprotein lipase, leading to a reduced incidence of 
hypertriglyceridemia. Unlike previous methods, some amphipathic 
peptides cause transient hypertriglyceridema in mice that lasts for 
less than 8 hours. Mice treated with these modified peptides have shown 
preserved liver function as they have failed to express increased 
levels of biomarkers for liver damage and prevent hypertriglyceridemia. 
Furthermore, treated mice show a reduced level of pro-atherogenic 
lipoproteins. This technology demonstrates specific control of lipid 
efflux and transport; a desirable property that gives it a significant 
advantage for treating or preventing a vast range of vascular diseases 
and their dyslipidemic precursors.
    This technology also encompasses a method for identifying non-
cytotoxic peptides that promote lipid efflux from cells and activates 
lipoprotein lipase.

Applications and Advantages

     Peptide treatment of dyslipidemic and vascular disorders.
     Transient hypertriglyceridemia with no reported toxicity.
     Method of identifying therapeutic non-cytotoxic peptides.
    Development Status: Pre-clinical.
    Inventor: Alan T. Remaley and Marcelo Amar (NHLBI).
    Publication: AT Remaley, F Thomas, JA Stonik, SJ Demosky, SE Bark, 
EB Neufeld, AV Bocharov, TG Vishnyakova, AP Patterson, TL Eggerman, S 
Santamarina-Fojo, HB Brewer. Synthetic amphipathic helical peptides 
promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-
independent pathway. J Lipid Res. 2003 Apr;44(4):828-836.
    Patent Status: U.S. Provisional Application No. 60/045,213 filed 15 
Apr 2008 (HHS Reference No. E-138-2008/0-US-01); PCT Application No. 
PCT/US2009/040560 filed 14 Apr 2009 (HHS Reference No. E-138-2008/0-
    Licensing Status: Available for licensing.
    Licensing Contact: Fatima Sayyid, M.H.P.M.; 301-435-4521; 

Methods for Treating or Ameliorating Fibrosis by Inhibiting the 
Interaction Between IL-21 Receptor (IL-21R) and IL-21

    Description of Invention: This invention includes methods for 
treating or ameliorating fibrosis by inhibiting the interaction between 
IL-21 Receptor (IL-21R) and IL-21 using either anti-IL21R monoclonal 
antibodies (or binding fragments of anti-IL-21R mAbs), anti-IL21 
monoclonal antibodies (or binding fragments of anti-IL-21 mAbs) or 
soluble IL-21R (or binding fragments of IL-21R). It is believed that 
the TH2 immune response, induced by IL-21, plays a major role in the 
pathogenesis of tissue fibrosis. Antagonism of IL-21R by anti-IL-21R 
monoclonal antibodies or the sequestration of IL-21 by soluble IL-

[[Page 38442]]

21R or anti-IL-21 monoclonal antibodies has been demonstrated to reduce 
TH2 immune responses associated with fibrosis in animal models.
    The causes of chronic tissue fibrosis are diverse and the market 
for a therapeutic that targets fibrosis is large. Fibrosis is 
associated with diverse causes which include: genetic diseases (such as 
cystic fibrosis); autoimmune diseases (such as scleroderma); chronic 
viral infections (such as hepatitis), parasitic infections (such as 
schistosomiasis); and occupational exposures to causative agents (such 
as asbestosis). Additionally, many cases of tissue fibrosis are 
    Application: The treatment or amelioration of tissue fibrosis.
    Inventors: Thomas A. Wynn (NIAID); Deborah A Young; Mary Collins; 
and Michael J. Grusby.
    Relevant Publication: J Pesce et al. The IL-21 receptor augments 
Th2 effector function and alternative macrophage activation. J Clin 
Invest 2006 Jul;116(7):2044-2055.
    Patent Status: U.S. patent application no. 11/402,885 (priority 
date April 14, 2005) and international patent applications including 
European patent application No. EP06/0750009 (HHS Reference No. E-250-
    Licensing Status: Available for non-exclusive licensing.
    Licensing Contact: Surekha Vathyam, Ph.D.; 301-435-4076; 
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate, or commercialize this invention. Please contact 
Nicole Mahoney at 301-435-9017 or mahoneyn@niaid.nih.gov for more 

Use of Discoidin Domain Receptor 1 (DDR1) and Agents That Affect the 
DDR1/Collagen Pathway

    Description of Invention: Dendritic cells (DCs) are pivotal 
antigen-presenting cells for initiation of an immune response. Indeed, 
dendritic cells provide the basis for the production of an effective 
immune response to a vaccine, particularly for antigens wherein 
conventional vaccination is inadequate. DCs are also important in the 
production on an immune response to tumor antigens.
    The present invention discloses methods of using the receptor 
tyrosine kinase discoidin domain receptor 1 (DDR1) to facilitate the 
maturation/differentiation of DCs or macrophages. Activating agents of 
DDR1 may be useful in the induction of highly potent, mature DCs or 
highly differentiated macrophages from DC precursors, such as 
monocytes. Use of this method may enhance the antigen presenting 
capabilities of the immune system, leading to a more effective overall 
immune response.
    Inventor: Teizo Yoshimura (NCI).

Relevant Publications

    1. H Kamohara et al. Discoidin domain receptor 1 isoform-a (DDR1a) 
promotes migration of leukocytes in three-dimensional collagen 
lattices. FASEB J. 2001 Dec;15(14):2724-2726.
    2. W Matsuyama et al. Interaction of discoidin domain receptor 1 
isoform b (DDR1b) with collagen activates p38 mitogen-activated protein 
kinase and promotes differentiation of macrophages. FASEB J. 2003 
    Patent Status: U.S. Application No. 10/507,385 filed 09 Sep 2004 
(HHS Reference No. E-083-2002/2-US-02).
    Licensing Status: Available for licensing.
    Licensing Contact: Betty B. Tong, Ph.D.; 301-594-6565; 

    Dated: July 28, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E9-18504 Filed 7-31-09; 8:45 am]